279262-15-6

Basic information

• Product Name: 4-(2-Ethoxyethoxy)phenylboronic acid
• Synonyms: 4-(2-Ethoxyethoxy)phenylboronic acid
• CAS NO: 279262-15-6
• Molecular Formula: C₁₀H₁₅BO₄
• Molecular Weight: 210.0347
• Product Categories: Boronate Ester;Boronic Acid;Potassium Trifluoroborate
• Mol File: 279262-15-6.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-(2-Ethoxyethoxy)phenylboronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-Ethoxyethoxy)phenylboronic acid(279262-15-6)
• EPA Substance Registry System: 4-(2-Ethoxyethoxy)phenylboronic acid(279262-15-6)

Safety Data

• Hazardous Substances Data: 279262-15-6(Hazardous Substances Data)

Usage

General Description

4-(2-Ethoxyethoxy)phenylboronic acid is a chemical compound with the molecular formula C10H15BO5. It is a boronic acid derivative that consists of a boronic acid group attached to a phenyl ring substituted with two ethoxyethyl groups. 4-(2-Ethoxyethoxy)phenylboronic acid is commonly used in organic synthesis and pharmaceutical research as a building block for the synthesis of various pharmaceuticals, agrochemicals, and materials. It is known for its ability to form stable complexes with diols, such as saccharides and catechols, making it a useful tool in the development of carbohydrate sensors and detection systems. Additionally, 4-(2-Ethoxyethoxy)phenylboronic acid has been studied for its potential applications in cancer therapy and sensor development due to its unique chemical properties and reactivity.

Upstream product

• 39255-20-4 1-bromo-4-[2-(ethoxy)ethoxy]benzene 
• 106-41-2 4-bromo-phenol 

Relevant articles and documents

Orally active CCR5 antagonists as anti-HIV-1 agents: Synthesis and biological activity of 1-benzothiepine 1,1-dioxide and 1-benzazepine derivatives containing a tertiary amine moiety

The search for orally active CCR5 antagonists was performed by chemical modification of the 1-benzothiepine 1,1-dioxide 3 and 1-benzazepine 4 lead compounds containing a tertiary amine moiety. Replacement of methyl group with a 2-(C2-4 alkoxy)ethoxy group at the 4-position on the 7-phenyl group of the 1-benzothiepine ring resulted in both enhanced activity and significant improvement in the pharmacokinetic properties upon oral administration in rats. Introduction of C2-4 alkyl, phenyl or (hetero)arylmethyl groups as the 1-substituent on the 1-benzazepine ring together with the 2-(butoxy)ethoxy group led to further increase of activity. Among the 1- benzazepine derivatives, the isobutyl (6i), benzyl (6o) or 1-methylpyrazol-4-ylmethyl (6s) compounds were found to exhibit highly potent inhibitory effects, equivalent to the injectable CCR5 antagonist 1, in the HIV-1 envelopemediated membrane fusion assay. In particular, compound 6s showed the most potent CCR5 antagonistic activity (IC50=2.7 nM) and inhibitory effect (IC50=1.2 nM) on membrane fusion, together with good pharmacokinetic properties in rats. The synthesis of 1-benzothiepine 1,1-dioxide and 1-benzazepine derivatives and their biological activity are described.